Edition:
United Kingdom

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

9.65USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$9.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
94,093
52-wk High
$26.00
52-wk Low
$9.05

Latest Key Developments (Source: Significant Developments)

Paratek Pharmaceuticals Q2 Loss Per Share $0.94
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.94.Q2 EARNINGS PER SHARE VIEW $-0.93 -- THOMSON REUTERS I/B/E/S.OMADACYCLINE PDUFA ACTION DATE SCHEDULED FOR OCTOBER 2018.COMPANY ON TRACK FOR A Q1 2019 OMADACYCLINE U.S. LAUNCH.ON TRACK FOR A Q1 2019 OMADACYCLINE U.S. LAUNCH.PARATEK PHARMACEUTICALS - AS OF JUNE 30 CO HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $321.1 MILLION.  Full Article

Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024
Thursday, 19 Apr 2018 

April 19 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK PHARMACEUTICALS, INC. PRICES $140 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024.PARATEK PHARMACEUTICALS INC - NOTES WILL PAY INTEREST SEMIANNUALLY IN ARREARS ON MAY 1 AND NOVEMBER 1 OF EACH YEAR AT RATE OF 4.75% PER YEAR.PARATEK PHARMACEUTICALS INC - NOTES WILL MATURE ON MAY 1, 2024.  Full Article

Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024
Wednesday, 18 Apr 2018 

April 18 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024.PARATEK PHARMACEUTICALS-INTENDS TO USE PROCEEDS, TOGETHER WITH EXISTING CAPITAL RESOURCES, TO FUND ONGOING AND FUTURE CLINICAL STUDIES OF OMADACYCLINE.  Full Article

Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK’S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA.PDUFA ACTION DATE IN OCTOBER 2018.IN NDA ACCEPTANCE LETTER, FDA STATED THAT NO FILING OR POTENTIAL REVIEW ISSUES WERE IDENTIFIED AT THE TIME.  Full Article

Paratek Announces $50.0 Mln Public Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.PARATEK PHARMACEUTICALS INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS SHARES OF COMMON STOCK.  Full Article

FDA Accepts New Drug Application For Seysara (Sarecycline)
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Allergan Plc ::FDA ACCEPTS NEW DRUG APPLICATION FOR SEYSARA™ (SARECYCLINE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE.PARATEK PHARMACEUTICALS INC - ALLERGAN EXPECTS PRESCRIPTION DRUG USER FEE ACT ACTION DATE TO OCCUR IN SECOND HALF OF 2018.  Full Article

Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Paratek Pharmaceuticals Inc ::PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​.  Full Article

Paratek Pharmaceuticals Q3 loss per share $0.77
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Paratek Pharmaceuticals Inc ::Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018.Q3 loss per share $0.77.Q3 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.Paratek Pharmaceuticals - ‍cash, cash equivalents and marketable securities sufficient to fund operating expenses, Capex requirements through Q2 2019​.  Full Article

UPDATE 1-U.S. FDA panel backs approval of Paratek's antibiotic

Aug 8 A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.